A coxib a day won't keep the doctor away

Lancet

Volumn 364, Issue 9435, 2004, Pages 639-640

  Topol, Eric J ^a   Falk, Gary W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; ROFECOXIB; VALDECOXIB; DRUG DERIVATIVE; ORGANIC COMPOUND; PROSTAGLANDIN SYNTHASE INHIBITOR;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERTENSION; NOTE; OSTEOARTHRITIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; PEPTIC ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; ORGANIC CHEMICALS; OSTEOARTHRITIS; PEPTIC ULCER;

EID: 4344648260     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16906-7     Document Type: Note

References (18)

1. Bombardier C, Laine L, Reicin A, et al, for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-28.
2. Silverstein FE, Faich G, Goldstein JL, et al, for the Celecoxib Long-term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study - a randomized controlled trial. JAMA 2000; 284: 1247-55.
3. Mukherjee D, Nissen S, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286:2001;954-959
4. Howard PA, Delafontaine P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk. J Am Coll Cardiol. 43:2004;519-525
5. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nature Rev Drug Discov. 2:2003;879-890
6. Hawkey CJ, Farkouh M, Gitton X, et al. Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib: study design and patient demographics. Aliment Pharmacol Ther. 20:2004;51-63
7. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 125:2003;1481-1487
8. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 363:2004;1751-1756
9. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 109:2004;2068-2073
10. Whelton A, White WB, Bello AE, Puma JA, Fort JG, and the SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90: 959-63.
11. Bogaty P, Brophy JM, Noel M, et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein. A randomized placebo-controlled study. Circulation. 110:2004;934-939
12. Chan FKL, Hung LCT, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 347:2002;2104-2110
13. Spiegel BMR, Targownik L, Dulai GS, Gralnek IM. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med. 138:2003;795-806
14. Jüni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ. 324:2002;1287-1288
15. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, Laupacis A. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ. 328:2004;1415-1416
16. Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol. 24:2004;246-255
17. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 107:2003;405-409
18. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet. 356:2002;118-123